Nilotinib (Nilotinib) domestic launch time and access methods

Nilotinib (Nilotinib), as a second-generation tyrosine kinase inhibitor (TKI), is mainly used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). The drug was developed by Novartis with the trade name "Tasigna" (Tasigna). It has been approved by the National Food and Drug Administration (NMPA) in China earlier for its official marketing. It was initially mainly used for patients with chronic phase or accelerated phase CML who were resistant or intolerant to imatinib (Imatinib), and was subsequently approved for first-line treatment of newly diagnosed patients.

In the domestic market, nilotinib has been included in the National Medical Insurance Drug List (Category B), but medical insurance reimbursement is limited to patient groups that meet specific indications, such as chronic or accelerated phasePh+ CML patients. The reimbursement ratio and specific costs vary slightly according to local medical insurance policies. Patients are recommended to go to a medical insurance designated hospital for detailed consultation when actually purchasing drugs. At present, the common specifications in China are 150mg*120 capsules, and the price per box is about 1 RMB. After reimbursement by medical insurance, the out-of-pocket part has been reduced, which greatly eases the financial burden of patients.

In addition to domestic regular hospitals and pharmacies obtaining the original drug Dashina, some patients will also pay attention to the price difference in overseas channels. For example, the price of each box of the original research version of nilotinib produced in India is about 2,000 RMB (150mg specification, quantity varies according to different brands), which is more affordable. In addition, some countries such as Laos also sell generic drugs, and the ingredients of the drugs are basically the same as those of the original research. For example, the version of 150mg*28 tablets produced by Laos Pharmaceutical Factory sells for only 1,000 yuan per box, attracting the attention of patients with heavy financial burdens.

To sum up, nilotinib has been approved for marketing in China and can cover the treatment costs for specific groups of people through medical insurance. Patients can purchase the original drug through formal domestic channels. At the same time, patients with certain financial or channel needs can also pay attention to overseas versions of drugs, but they must carefully choose the source and version of drugs under the guidance of a doctor, and avoid purchasing counterfeit drugs or low-quality generic drugs to ensure the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/